Mirum Pharmaceuticals, Inc. (MIRM)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Mirum Pharmaceuticals, Inc. reported revenue of $521.31M, up 54.7% from the prior year. The company ran a net loss, with a net margin of -4.5%. It held $842.81M in total assets against $528.12M in total liabilities.
Key ratios (FY2025)
-4.2%
Operating margin
-4.5%
Net margin
-7.4%
Return on equity
+54.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $521.31M | $336.89M | $186.37M | $77.06M | $19.14M | — | — | — |
| Operating Income | -$22.14M | -$87.61M | -$109.15M | -$131.22M | -$173.41M | -$104.30M | -$54.74M | — |
| Net Income | -$23.36M | -$87.94M | -$163.41M | -$135.66M | -$83.99M | -$103.27M | -$52.55M | — |
| EPS (Diluted) | $-0.47 | $-1.85 | $-4.00 | $-4.02 | $-2.77 | — | — | — |
| Total Assets | $842.81M | $670.75M | $646.62M | $352.91M | $294.65M | $240.86M | $146.71M | $51.98M |
| Total Liabilities | $528.12M | $445.11M | $397.95M | $210.87M | $174.44M | $68.77M | $16.36M | $2.45M |
| Shareholders' Equity | $314.69M | $225.64M | $248.67M | $142.04M | $120.21M | $172.09M | $130.35M | -$17.31M |
| Cash & Equivalents | $296.68M | $222.50M | $286.33M | $28.00M | $31.34M | $142.09M | $11.97M | $51.96M |
| Operating Cash Flow | $55.83M | $10.32M | -$70.94M | -$120.14M | -$132.76M | -$89.08M | -$39.36M | — |
| Capital Expenditures | $954.0K | $993.0K | $109.0K | $278.0K | $24.0K | $225.0K | $281.0K | — |
| Shares Outstanding | 51.90M | 48.34M | 46.72M | 36.96M | 30.58M | 29.78M | 22.60M | 636.7K |